Phase 2 And 3 Trials Of Sputnik V Happening In India: Russian Vaccine Firm Chief
Kirill Dmitriev, CEO of Russian Direct Investment Fund, the agency spearheading the development and production of coronavirus vaccine Sputnik V in Russia, says initial results have shown an efficacy rate of 92%. "We are sharing results with India's drug regulator. The phase 2 and 3 of the trial are happening in India. We have an agreement that India will use Russia's data," he said.
